VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a retrospective analysis evaluating the prognostic value of circulating peripheral blood blasts in cohorts of patients with primary myelofibrosis who were treated with/without ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter